MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/1759720x221116409

Медицинская библиотека · Therapeutic advances in musculoskeletal disease · 2022

Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout.

Eun Yeonghee, Han Heewon, Kim Kyunga, Kang Seonyoung, Lee Seulkee, Kim Hyungjin, Lee Jaejoon, Koh Eun-Mi, Cha Hoon-Suk

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

In previous studies, cardiovascular (CV) risk was increased in patients with gout. The effects of uric acid-lowering therapy on CV risk in gout patients have been investigated in numerous studies; however, allopurinol and benzbromarone have rarely been compared.

OBJECTIVES

To compare CV risk based on allopurinol and benzbromarone treatment in Korean gout patients.

DESIGN

A nationwide population-based retrospective cohort study.

METHODS

We used South Korea database of the Health Insurance Review and Assessment (HIRA) service to identify gout patients ⩾18 years of age who newly started allopurinol or benzbromarone between 2009 and 2015. The primary outcome of the study was the occurrence of a composite CV endpoint, which included coronary revascularization, hospitalization due to myocardial infarction, ischemic stroke, and transient ischemic attack. Cox proportional hazard regression analysis and Kaplan-Meier curves were used for analysis.

RESULTS

The study included 257,097 allopurinol initiators and 7868 benzbromarone initiators. Compared with allopurinol initiators, the adjusted hazard ratio (aHR) of the composite CV endpoint of benzbromarone initiators was 1.01 [95% confidence interval (CI): 0.83-1.21], which was not significantly different. The results did not change even when 1:3 propensity score matching was performed for baseline characteristics. In subgroup analysis of high-risk patients with CV disease, significant difference was not observed between allopurinol and benzbromarone initiators.

CONCLUSION

In this study, significant difference was not found in CV risk between allopurinol and benzbromarone initiators. In the high-CV-risk group, the incidence of CV events did not differ between allopurinol and benzbromarone initiators.

Для цитирования: Eun Yeonghee, Han Heewon, Kim Kyunga, Kang Seonyoung, Lee Seulkee, Kim Hyungjin, Lee Jaejoon, Koh Eun-Mi, Cha Hoon-Suk. Cardiovascular risk associated with allopurinol or benzbromarone treatment in patients with gout.. Therapeutic advances in musculoskeletal disease. 2022. DOI: 10.1177/1759720x221116409.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.